Raymond, 62, from Mexico City, began experiencing shortness of breath in 2022, leading to a stage III non-small cell lung cancer diagnosis. “My first thought was, ‘This is it,’ but my son pushed for a second opinion,” he says. His new team recommended genomic testing, which identified a specific mutation responsive to a targeted drug. “The treatment made me tired, but seeing my tumor shrink on scans after two months gave me strength,” Raymond explains. “My coach suggested adding mistletoe therapy to boost my appetite, and it worked—I could finally eat without nausea.” Now, 18 months later, his cancer is stable, and he’s back to weekly soccer games with friends. “Lung cancer doesn’t have to stop you. The right tests found a drug that targets my cancer, not just any cancer. That’s the difference.” He advises: “Don’t settle for ‘standard care.’ Ask about tests that can pinpoint what will work for you. It might just save your life.”